Calidi Biotherapeutics stock was up 171.84% in pre-market trading on Wednesday, following a 39.47% rally yesterday. However, ...

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today ...

Calidi Biotherapeutics Inc. CLDI stock surged by 39.47% in the after-hours trading session on Tuesday. The stock price ...

Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease ...

Ladenburg Thalmann & Co, Inc. is acting as the exclusive placement agent for the offering.

Calidi Biotherapeutics Inc. is taking a bold approach to this challenge with a next-generation platform designed to deliver genetic medicines directly to both primary and metastatic tumors.

Calidi Biotherapeutics Inc. (NYSE American: CLDI) ('Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to ...

Calidi Biotherapeutics announced a public offering of 5 million shares at $0.85 each, aiming for $4.25 million in proceeds. Quiver AI Summary Calidi Biotherapeutics, Inc. announced the pricing of ...

Calidi Biotherapeutics secures $4.6 million through warrant exerciseCalidi Biotherapeutics is developing targeted therapies designed to deliver genetic medicines to disease sites. The company’s ...

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company pioneering the development of targeted therapies that can deliver genetic medicines to sites of disease.